Share this article
Share this article
SHANGHAI and GAITHERSBURG, Md., April 26, 2021 /PRNewswire/ I-Mab (the Company ) (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced positive topline results from its regional multi-center, randomized, double-blind and placebo-controlled phase 2 study (NCT03235752) evaluating the efficacy and safety of olamkicept (also known as TJ301) administered intravenously biweekly in patients with active ulcerative colitis (UC).
Olamkicept is the only clinical stage selective IL-6 inhibitor that works through the trans-signaling mechanism. IL-6 is an important driver cytokine in the propagation and maintenance of chronic inflammation in autoimmune diseases, such as UC.
I-Mab Announces Positive Topline Phase 2 Results for Olamkicept in Ulcerative Colitis
biospace.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biospace.com Daily Mail and Mail on Sunday newspapers.
Adalimumab Earns FDA Approval for Ulcerative Colitis in Children
medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
ABBVie today announced that the U.S. Food and Drug Administration approved HUMIRA ® for the treatment of moderately to severely active ulcerative colitis in pediatric patients 5 years of age and older. In clinical trials, HUMIRA induced clinical remission at Week 8 and maintained remission at Week 52 in patients who responded at Week 8. 1,2 “Ulcerative colitis can have a profound effect on children and for too …
ABBVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) approved HUMIRA ® (adalimumab) for the treatment of moderately to severely active ulcerative colitis in pediatric patients 5 years of age and older. In clinical trials, HUMIRA induced clinical remission at Week 8 and maintained remission at Week 52 in patients who responded at Week 8. 1,2